CRISPR Therapeutics Announces Transition of Chief Operating Officer
CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.
CRISPR Therapeutics (Nasdaq: CRSP) ha annunciato che il Chief Operating Officer Julianne Bruno si dimetterà dalla sua posizione a partire dall'11 aprile 2025, per perseguire opportunità esterne. Bruno ha lavorato per l'azienda per sei anni, durante i quali la sua leadership è stata fondamentale per il progresso dei programmi di ematologia e oncologia dell'azienda. Il CEO Samarth Kulkarni ha riconosciuto il suo contributo nel migliorare il modello operativo dell'azienda e nelle varie iniziative trasversali.
CRISPR Therapeutics (Nasdaq: CRSP) anunció que la Directora de Operaciones Julianne Bruno dejará su puesto a partir del 11 de abril de 2025, para buscar oportunidades externas. Bruno ha trabajado en la empresa durante seis años, durante los cuales su liderazgo fue importante para avanzar en los programas de hematología y oncología de la compañía. El CEO Samarth Kulkarni reconoció sus contribuciones en la maduración del modelo operativo de la empresa y en diversas iniciativas interfuncionales.
CRISPR Therapeutics (Nasdaq: CRSP)는 최고 운영 책임자인 Julianne Bruno가 2025년 4월 11일부터 외부 기회를 추구하기 위해 직위에서 물러날 것이라고 발표했습니다. Bruno는 회사에서 6년 동안 근무했으며, 그 동안 그녀의 리더십은 회사의 혈액학 및 종양학 프로그램을 발전시키는 데 중요한 역할을 했습니다. CEO Samarth Kulkarni는 회사의 운영 모델을 성숙시키고 다양한 교차 기능 이니셔티브를 추진하는 데 기여한 그녀의 노력에 감사를 표했습니다.
CRISPR Therapeutics (Nasdaq: CRSP) a annoncé que la Directrice des opérations, Julianne Bruno, quittera son poste à compter du 11 avril 2025, pour poursuivre des opportunités externes. Bruno a servi l'entreprise pendant six ans, période durant laquelle son leadership a été essentiel pour faire avancer les programmes d'hématologie et d'oncologie de l'entreprise. Le PDG Samarth Kulkarni a reconnu ses contributions à la maturation du modèle opérationnel de l'entreprise et à diverses initiatives interfonctionnelles.
CRISPR Therapeutics (Nasdaq: CRSP) gab bekannt, dass die Chief Operating Officer Julianne Bruno mit Wirkung zum 11. April 2025 von ihrer Position zurücktritt, um externe Möglichkeiten zu verfolgen. Bruno war sechs Jahre lang im Unternehmen tätig, während derer ihre Führung entscheidend für den Fortschritt der hämatologischen und onkologischen Programme des Unternehmens war. CEO Samarth Kulkarni erkannte ihre Beiträge zur Weiterentwicklung des Betriebsmodells des Unternehmens und verschiedener funktionsübergreifender Initiativen an.
- None.
- Departure of key executive (COO) could create temporary leadership gap
- Loss of experienced leader who advanced critical hematology and oncology programs
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025.
“Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “I want to thank her for her contributions and wish her all the best in her future endeavors and continued success.”
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics COO Julianne Bruno leaving the company?
How long has Julianne Bruno served as COO at CRISPR Therapeutics (CRSP)?
What were Julianne Bruno's main achievements at CRISPR Therapeutics (CRSP)?
Has CRISPR Therapeutics (CRSP) announced a replacement for the departing COO?
